Cas:5625-98-9 2-morpholin-4-ylacetamide manufacturer & supplier

We serve Chemical Name:2-morpholin-4-ylacetamide CAS:5625-98-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-morpholin-4-ylacetamide

Chemical Name:2-morpholin-4-ylacetamide
CAS.NO:5625-98-9
Synonyms:2-MORPHOLINOACETAMIDE;morpholinoacetamide;4-Morpholineacetamide;morpholinoethyl amide;Morpholino-essigsaeure-amid
Molecular Formula:C6H12N2O2
Molecular Weight:144.17200
HS Code:2934999090

Physical and Chemical Properties:
Melting point:122ºC
Boiling point:298.8ºC at 760mmHg
Density:1.135g/cm3
Index of Refraction:1.487
PSA:55.56000
Exact Mass:144.09000
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-MORPHOLINOACETAMIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Morpholino-essigsaeure-amid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,morpholinoethyl amide Use and application,2-MORPHOLINOACETAMIDE technical grade,usp/ep/jp grade.


Related News: At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. 2-morpholin-4-ylacetamide manufacturer The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful. 2-morpholin-4-ylacetamide supplier From the perspective of product structure, the varieties of these enterprises are mainly concentrated in vitamins, antipyretics and analgesics, antibiotics and corticosteroids (ie bulk drug substances). 2-morpholin-4-ylacetamide vendor At ASH, scientists from the Company and MSK presented new in vivo preclinical data demonstrating that FT819 exhibits durable tumor control and extended survival. 2-morpholin-4-ylacetamide factory The third-to-market BTK inhibitor is also looking to report top-line results from a front-line trial later this year. Imbruvica could feel more pressure if that study also turns out successful.